LU88122A1 - Anticorps purifies specifiquement developpes contre le cdw52 - Google Patents
Anticorps purifies specifiquement developpes contre le cdw52 Download PDFInfo
- Publication number
- LU88122A1 LU88122A1 LU88122A LU88122A LU88122A1 LU 88122 A1 LU88122 A1 LU 88122A1 LU 88122 A LU88122 A LU 88122A LU 88122 A LU88122 A LU 88122A LU 88122 A1 LU88122 A1 LU 88122A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- antibody
- column
- cdw52
- prepn
- purified
- Prior art date
Links
- 102100024217 CAMPATH-1 antigen Human genes 0.000 title 1
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229920002684 Sepharose Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000001542 size-exclusion chromatography Methods 0.000 abstract 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909022547A GB9022547D0 (en) | 1990-10-17 | 1990-10-17 | Purified immunoglobulin |
PCT/GB1991/001816 WO1992007084A1 (en) | 1990-10-17 | 1991-10-17 | Purified cdw52-specific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
LU88122A1 true LU88122A1 (fr) | 1993-03-15 |
Family
ID=10683866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU88122A LU88122A1 (fr) | 1990-10-17 | 1992-05-27 | Anticorps purifies specifiquement developpes contre le cdw52 |
Country Status (29)
Country | Link |
---|---|
US (1) | US5644036A (es) |
EP (1) | EP0504363B2 (es) |
JP (1) | JP2638680B2 (es) |
KR (2) | KR960015399B1 (es) |
AT (2) | ATE162552T1 (es) |
AU (3) | AU658926B2 (es) |
BE (1) | BE1004226A5 (es) |
BR (1) | BR1100358A (es) |
CA (1) | CA2069481C (es) |
CH (2) | CH681305A5 (es) |
DE (1) | DE69128774T3 (es) |
DK (1) | DK0504363T4 (es) |
ES (2) | ES2112865T5 (es) |
FI (2) | FI110003B (es) |
FR (2) | FR2668164A1 (es) |
GB (2) | GB9022547D0 (es) |
GR (3) | GR910100425A (es) |
HU (1) | HUT64601A (es) |
IE (1) | IE913560A1 (es) |
IL (3) | IL102726A (es) |
IT (1) | IT1250064B (es) |
LU (1) | LU88122A1 (es) |
MX (1) | MX9203794A (es) |
MY (2) | MY136210A (es) |
NZ (2) | NZ240247A (es) |
PT (2) | PT99248B (es) |
TW (1) | TW283710B (es) |
WO (1) | WO1992007084A1 (es) |
ZA (2) | ZA918259B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
MY115415A (en) * | 1991-10-15 | 2003-06-30 | Wellcome Found | Medicaments. |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
GB9300501D0 (en) * | 1993-01-09 | 1993-03-03 | Wellcome Found | Purification of immunoglobulin |
WO1997004803A1 (fr) † | 1995-08-01 | 1997-02-13 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
PL188192B1 (pl) | 1996-02-09 | 2004-12-31 | Abbott Lab Bermuda Ltd | Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen |
GB9603256D0 (en) * | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US20030023043A1 (en) * | 2000-03-02 | 2003-01-30 | Kazuhisa Uchida | Method of separating and purifying protein |
WO2002072615A1 (fr) * | 2001-03-09 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Methode de purification de proteines |
DK1404428T3 (da) * | 2001-06-05 | 2006-10-30 | Genetics Inst Llc | Fremgangsmåder til oprensning af stærkt anioniske proteiner |
GB0220894D0 (en) * | 2002-09-09 | 2002-10-16 | Millipore Uk Ltd | Method of separation |
CA2497364C (en) | 2002-09-11 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
CN102174533A (zh) | 2002-10-15 | 2011-09-07 | 英特塞尔股份公司 | 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途 |
GB0304576D0 (en) * | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
BRPI0417993A (pt) * | 2003-12-22 | 2007-04-27 | Genzyme Corp | anticorpo anti-cd52 para tratamento da diabetes |
KR101660575B1 (ko) * | 2005-03-11 | 2016-09-27 | 와이어쓰 엘엘씨 | 약한 분배성 크로마토그래피법 |
MY195714A (en) | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
CN102438654A (zh) | 2009-05-13 | 2012-05-02 | 基酶有限公司 | 治疗狼疮的方法和组合物 |
EP3683317A3 (en) | 2009-05-13 | 2020-09-30 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
EP2695889A1 (en) * | 2009-12-29 | 2014-02-12 | Dr. Reddy's Laboratories Limited | Protein purification by ion exchange |
EP3266793A1 (en) | 2010-06-21 | 2018-01-10 | Kyowa Hakko Kirin Co., Ltd. | Method for purifying protein using amino acid |
RU2467783C2 (ru) * | 2010-07-30 | 2012-11-27 | Закрытое акционерное общество "БиоХимМак СТ" | Способ хроматографического выделения иммуноглобулина |
KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9650411B2 (en) | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
SG11201504249XA (en) | 2012-09-02 | 2015-07-30 | Abbvie Inc | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
BR112016014824A2 (pt) | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
EP3330279B1 (en) | 2015-07-31 | 2022-04-06 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying composition comprising antibodies with anionic polymer |
WO2018022628A1 (en) | 2016-07-25 | 2018-02-01 | Cephalon, Inc. | Affinity chromatography wash buffer |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
US20220177518A1 (en) | 2019-03-29 | 2022-06-09 | Asahi Kasei Medical Co., Ltd. | Method for purifying protein |
WO2020209267A1 (ja) | 2019-04-08 | 2020-10-15 | 旭化成メディカル株式会社 | タンパク質含有溶液精製用ポリアミド媒体及びその製造方法 |
CA3136398A1 (en) | 2019-04-10 | 2020-10-15 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying fc region-modified antibody |
JPWO2022260091A1 (es) | 2021-06-10 | 2022-12-15 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
AU618989B2 (en) * | 1988-02-12 | 1992-01-16 | British Technology Group Limited | Improvements in or relating to antibodies |
-
1990
- 1990-10-17 GB GB909022547A patent/GB9022547D0/en active Pending
-
1991
- 1991-10-16 MY MYPI92001385A patent/MY136210A/en unknown
- 1991-10-16 ZA ZA918259A patent/ZA918259B/xx unknown
- 1991-10-16 IT ITRM910788A patent/IT1250064B/it active IP Right Grant
- 1991-10-16 GR GR910100425A patent/GR910100425A/el unknown
- 1991-10-16 PT PT99248A patent/PT99248B/pt not_active IP Right Cessation
- 1991-10-16 FR FR9112738A patent/FR2668164A1/fr active Granted
- 1991-10-16 NZ NZ240247A patent/NZ240247A/en not_active IP Right Cessation
- 1991-10-16 BE BE9100946A patent/BE1004226A5/fr not_active IP Right Cessation
- 1991-10-16 MY MYPI91001909A patent/MY119030A/en unknown
- 1991-10-16 NZ NZ244114A patent/NZ244114A/en not_active IP Right Cessation
- 1991-10-16 IE IE356091A patent/IE913560A1/en not_active IP Right Cessation
- 1991-10-16 IL IL10272691A patent/IL102726A/en not_active IP Right Cessation
- 1991-10-16 TW TW080108178A patent/TW283710B/zh not_active IP Right Cessation
- 1991-10-16 ZA ZA926191A patent/ZA926191B/xx unknown
- 1991-10-16 IL IL99761A patent/IL99761A0/xx unknown
- 1991-10-17 HU HU9202000A patent/HUT64601A/hu unknown
- 1991-10-17 CH CH1901/92A patent/CH681305A5/fr not_active IP Right Cessation
- 1991-10-17 EP EP91917891A patent/EP0504363B2/en not_active Expired - Lifetime
- 1991-10-17 ES ES91917891T patent/ES2112865T5/es not_active Expired - Lifetime
- 1991-10-17 KR KR1019920701427A patent/KR960015399B1/ko not_active IP Right Cessation
- 1991-10-17 DK DK91917891T patent/DK0504363T4/da active
- 1991-10-17 CH CH2655/92A patent/CH681455A5/fr not_active IP Right Cessation
- 1991-10-17 ES ES09250029A patent/ES2081742B1/es not_active Expired - Lifetime
- 1991-10-17 CA CA002069481A patent/CA2069481C/en not_active Expired - Lifetime
- 1991-10-17 AT AT91917891T patent/ATE162552T1/de not_active IP Right Cessation
- 1991-10-17 AT AT0900791A patent/ATA900791A/de not_active Application Discontinuation
- 1991-10-17 DE DE69128774T patent/DE69128774T3/de not_active Expired - Lifetime
- 1991-10-17 JP JP3516509A patent/JP2638680B2/ja not_active Expired - Lifetime
- 1991-10-17 WO PCT/GB1991/001816 patent/WO1992007084A1/en active IP Right Grant
-
1992
- 1992-02-28 GB GB9209529A patent/GB2253397A/en not_active Withdrawn
- 1992-05-25 FI FI922380A patent/FI110003B/fi not_active IP Right Cessation
- 1992-05-27 LU LU88122A patent/LU88122A1/xx unknown
- 1992-06-17 FI FI922824A patent/FI110002B/fi not_active IP Right Cessation
- 1992-06-29 MX MX9203794A patent/MX9203794A/es unknown
- 1992-08-04 IL IL102726A patent/IL102726A0/xx unknown
- 1992-08-13 FR FR9209998A patent/FR2677997A1/fr not_active Withdrawn
- 1992-09-23 AU AU25321/92A patent/AU658926B2/en not_active Expired
- 1992-10-20 PT PT100988A patent/PT100988B/pt not_active IP Right Cessation
- 1992-10-20 GR GR920100471A patent/GR920100471A/el unknown
- 1992-10-30 KR KR1019920702699A patent/KR100193314B1/ko not_active IP Right Cessation
-
1994
- 1994-08-11 AU AU70242/94A patent/AU7024294A/en not_active Abandoned
- 1994-10-07 US US08/319,598 patent/US5644036A/en not_active Expired - Lifetime
-
1997
- 1997-04-28 BR BR1100358-8A patent/BR1100358A/pt active IP Right Grant
- 1997-11-13 AU AU45218/97A patent/AU716402B2/en not_active Expired
-
1998
- 1998-04-10 GR GR980400777T patent/GR3026588T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU88122A1 (fr) | Anticorps purifies specifiquement developpes contre le cdw52 | |
MX9603637A (es) | Purificacion de anticuerpo. | |
EP0185034A4 (es) | ||
AU7067287A (en) | Method and apparatus for separating proteins | |
FR2487642B2 (fr) | Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions | |
Dimitrijevic et al. | Purification and characterization of an estrogen-binding peroxidase from human fetuses | |
Ninfali et al. | Goat immunoglobulin purification on phosphocellulose and DEAE Affi-Gel blue | |
ATE118782T1 (de) | Reinigungsverfahren für interferon. | |
von Bahr-Lindström et al. | Analytical and Preparative Applications of High-Performance Liquid Chromatography. Comparisons with Other Methods | |
FR2411202A1 (fr) | Procede d'extraction et de purification de la globuline transporteur d'hormones thyroidiennes tbg |